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Open access under the ElBackground: Canova activates macrophages and indirectly induces lymphocyte proliferation. Here we
evaluated the effects of Canova in cyclophosphamide-treated non-human primates.
Methods: Twelve Cebus apella were evaluated. Four animals were treated with Canova only. Eight ani-
mals were treated with two doses of cyclophosphamide (50 mg/kg) and four of these animals received
Canova. Body weight, biochemistry and hematologic analyses were performed for 40 days. Micronucleus
and comet assays were performed for the evaluation of DNA damage.
Results: We observed that cyclophosphamide induced abnormal WBC count in all animals. However,
the group treated with cyclophosphamide plus Canova presented a higher leukocyte count than that
which received only cyclophosphamide. Cyclophosphamide induced micronucleus and DNA damage in
all animals. The frequency of these alterations was signiﬁcantly lower in the Canova group than in the
group without this medicine.
Conclusions: Our results demonstrated that Canova treatment minimizes cyclophosphamide myelotox-
icity in C. apella.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Cancer is a leading cause of death worldwide (WHO, 2010). Sev-
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sevier OA license.protecting patients from adverse effects of these intensive thera-
pies has been a goal of clinical oncologists (Bukowski, 1999).
For over 40 years, cyclophosphamide (CP) has been in clinical
use for the treatment of malignant and nonmalignant disorders
(Hosseinimehr and Karami, 2005). However, CP is an alkylating
agent that produces gene mutations, chromosome aberrations,
micronuclei (MN) and sister chromatid exchanges (Anderson
et al., 1995). CP causes adverse effects especially in the hematopoi-
etic system (primarily represented by leukopenia), and the gastro-
intestinal tract and also can produce secondary tumors due to its
genotoxicity (Schuurman et al., 2005).
New adjuvant therapeutic approaches to known therapies and
chemoprotectants, for example glutathione, amifostine and quer-
cetin (Jena et al., 2010), have been developed as methods to protect
normal tissues from the toxicity of antineoplastic agents without
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quality of life during anticancer treatment (Stolarska et al., 2006).
Canova (CA) is a complex homeopathic medicine indicated for
patients whose immune system is depressed. CA treatment seems
to enhance an individual’s ability to trigger a speciﬁc immunologic
response against several pathological conditions (Cesar et al.,
2008).
It was previously demonstrated that CA treatment induces mac-
rophage activation and indirectly induces lymphocyte proliferation
in vivo and in vitro (Abud et al., 2006; Burbano et al., 2009; Cesar
et al., 2008; Da Rocha Piemonte and De Freitas Buchi, 2002; de
Oliveira et al., 2006; Lopes et al., 2006; Pereira et al., 2005). More-
over, our research group has previously demonstrated that CA
treatment does not induce cytotoxic or genotoxic effects at the
chromosomal level in vitro (Seligmann et al., 2003).
Due to their phylogenetic proximity to humans, non-human
primates offer a useful model for basic research into genetic and
immunopathogenesis mechanisms as well as for the development
and validation of new therapies for several diseases. Non-human
primates are also of particular relevance in evaluating the potential
toxicity of drugs and environmental agents.Cebus apella is an inter-
esting model for drug studies, since they can be easily housed in
Primate Research Centers due to their ﬂexibility, opportunism,
adaptability, small size, and with annual reproduction of these ani-
mals being possible in primatology centers. Currently, Cebus spe-
cies are frequently used in neuroscience, dentistry, reproduction,
and behavioral research (Torres et al., 2010).
Since CA treatment leads to lymphocyte differentiation and pro-
liferation (Cesar et al., 2008), the aim of the present study was to
evaluate whether this drug has a protective effect against the tox-
icity caused by chemotherapy. We analyzed the effects of CA med-
icine in CP-treated non-human primates, C. apella.2. Materials and methods
2.1. Canova
‘Canova do Brazil’, a Brazilian company, holds the international patent of this
medicine (CANOVA, 2012). Experiments were performed with commercial CA do-
nated by ‘Canova do Brazil’.
CA is an aqueous, colorless and odorless solution. The Hahnemannian homeo-
pathic method used to prepare the Canova medicine is described in the Brazilian
homeopathic pharmacopoeia (CPRFB, 1997). dH units (decimal Hahnemannian)
were used. The number before the dH is the number of times the decimal dilution
is made; 10 dH would be 1  1010. The ﬁnal product contains Aconitum napellus
dH20, Apis melliﬁca dH19, Arsenicum album dH17, Asa foetida dH20, Baryta carbonica
dH20, Bryonia alba dH14, Calcarea carbonica dH20, Conium maculatum dH16, Ipeca-
cuanha dH13, Lachesis muta dH18, Lycopodium clavatum dH20, Pulsatilla nigricans
dH13, Rhus toxicodendrum dH17, Ricinus communis dH14, Silicea dH18, Thuya occi-
dentalis dH16, Veratrum album dH20 and less than 1% ethanol in distilled water.
In natural medicine, each of these components is used separately in the treatment
of different diseases, including facial paralysis, joint pain, gout, uterine and colorec-
tal polyps, and cancer.Fig. 1. Time line of drug treatments and blood collections. , Animals from CP-2.2. Animals and treatments
Twelve male adult C. apella (6–8 years old) were evaluated (2.8–3.4 kg). All ani-
mals were born and bred in captivity in Centro Nacional de Primatas (CENP), Pará
State, Brazil. The C. apella is easily available in CENP.
In this study, the details of animal welfare and steps taken to ameliorate suffer-
ing were in accordance with the recommendations of the Weatherall report, ‘‘The
use of non-human primates in research’’ (Sir David Weatherall FRS FMedSci’s
working group, 2006). This study received the approval of the Ethics Committee
of Universidade Federal do Pará (PARECER MED002/2007).
Animals were identiﬁed with microchips and were individually housed in the
CENP. All animals were maintained in aluminum squeeze cages
(80  90  80 cm) under a natural photoperiod. The animals were fed with fresh
fruit, vegetables and commercial food pellets (FOXY Junior Supreme 28% crude pro-
tein; PROVIMI, Brazil). Water was given ad libitum.
Before the study, animals were conﬁned in individual cages during 40–50 days.
Blood, urine and stool tests were performed and the body weight was recorded. The
animals received appropriated veterinary care if any abnormality was detected.
Animals without standard body weight get speciﬁc diet. After 40–50 days, new tests
were performed and the animals which presented some health problem were re-
moved from the study (3 of 15 animals). Among the three animals excluded from
entry in the study, two animals presented the weight below the average and the
other animal presented some hematology parameters suggestive of anemia.
According to a basic veterinary examination, all animals were considered
healthy at the time of the ﬁrst blood sampling. This was conﬁrmed by the animals’
behavior as judged by the veterinary check.
The animals were randomly divided into three groups of four C. apella each. One
group received only CP (CP group), the second group was treated with CA only (CA
group) and the third group was treated with both CP and CA (CP + CA group).
The CP and CP + CA groups were treated with 50 mg/kg B.W. CP (Cytoxan,
Bristol–Myers Oncology, USA) dissolved in sterile physiological saline solution on
the day of dosing. The CP dose level was determined based on previous studies with
nonhuman primates which evaluated different applications of CP (da Costa et al.,
2011; Schuurman et al., 2005). All eight animals received CP twice (day 1 and
20). The interval between CP treatments was determined considering the recovery
of leukocyte count.
The CA and CP + CA groups received injections of 1.67 ll/g commercial CA
(intravenous form) on day 1 and 20. Those in the CP + CA group were administered
the CP at the same time. The CA dose level was determined according the study of
Moreira et al. (2012) in C. apella which evaluated different applications of CA.
The animals were weighed daily and the doses calculated at that time. CP and
CA were injected by slow infusion in the right femoral vein of C. apella in a single
dose (Sharma et al., 1999).2.3. Animal evaluation
Two days before the infusions (day 1 and 0), blood samples of all animals were
collected for the determination of hematologic parameters and for the evaluation of
hepatic and renal functions (Fig. 1). These samples were used as base values for
these analyses. For genotoxicity analyses, the blood sample of day 0 was used as
base values.
During treatment periods, animals were inspected daily and clinical symptoms
recorded. For minor manipulation or close observation, physical restraint (squeeze
cages) and chemical restraint were used. Daily, the animal were sedated with ket-
amine hydrochloride (Ketaral, 15 mg/kg), and, then, body weight was determined
and about 3 ml of peripheral blood was collected for serum biochemistry and hema-
tologic analyses. The blood samples were obtained from femoral veins and the vol-
ume of blood collected was based on each animal’s weight in accordance with the
‘‘Guide for the care and use of laboratory animals’’ (National Research Council,
1996).group that were euthanized. CP, cyclophosphamide. CA, Canova medicine.
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System (Johnson & Johnson, USA) and included glucose, urea nitrogen, creatinine,
total protein, albumin, globulin, total bilirubin, cholesterol, triglyceride, alanine
aminotransferase, aspartate aminotransferase, c-glutamyl transpeptidase, lactate
dehydrogenase, creatine kinase, amylase, calcium, inorganic phosphorus, sodium,
potassium, and chloride. Clinical hematology included red blood cell count, hemo-
globin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin,
mean corpuscular hemoglobin concentration, reticulocyte count, platelet count,
white blood cell (WBC) and differential (segmented neutrophil, lymphocyte,
monocyte, eosinophil and basophile) counts. Hematology analyses were per-
formed using an automated blood cell counter (CC-530, Celm, Brazil). Manual
WBC differential was obtained by counting 100 leukocytes in Wright-stained
blood smear. Reference values for male adult animals were previously described
by Riviello and Wirz (2001). Most of the analyses were performed for 40 days
(Fig. 1).
Alterations in the hematology parameters, especially WBC and differential, rep-
resented major CP adverse effects observed in the laboratory parameters analyzed,
as also previously observed (Schuurman et al., 2005). Thus, our results focus mainly
on these parameters.
All animals were carefully monitored to avoid pain signals, discomfort, stress or
infections before, during, and after drug injections. Allergic and toxic chemo-related
reactions were also evaluated, including the analysis of chromosomal aberration
and DNA damage due to CP effects, through micronucleus and comet assays.2.4. Animal’s euthanasia
Animals suffering and with presumed terminal illness due to serious adverse
side effects were euthanized. Animals were euthanized by intravenous administra-
tion of Ketaral (Cetamine chloride, 50 mg/kg), Dormonid (Midazolam, 50 mg/kg)
and Methotrimeprazine (Levomepromazine, 50 mg/kg). After euthanasia, the ani-
mals were submitted for necropsy and organs and body ﬂuids were collected for
laboratory analysis. Before euthanasia, a blood sample was also collected for comet
assay.2.5. Genotoxicity analyses
To evaluate the in vivo genotoxicity of CA medicine, we performed in vivo comet
and MN assays. These two tests have been successfully combined to determine drug
genotoxicity in vivo since they presented differences in sensitivity, endpoints mea-
sured and the type of data generated (Vasquez, 2010). While DNA damage, mea-
sured by the comet assay, cause structural chromosome aberrations following
errors of DNA replication, micronucleus arises from acentric fragments, one of the
structural aberrations, when the fragment its failed to be included in a daughter nu-
clei and is left in the cytoplasm (Igarashi et al., 2010). Combining these two assays
allow the reduction of animal use in safety testing (Vasquez, 2010).2.5.1. Lymphocyte-MN assay
We previously observed that the highest CA effect in lymphocyte culture occurs
after 72 h. Peripheral blood samples were collected from all C. apella 24 h after CP,
CA, or CP + CA treatments (day 2 and 21, respectively; Fig. 1). Short-term lympho-
cyte cultures were initiated according to standard protocol (Preston et al., 1987).
Lymphocytes were cultured in HAM-F10 medium (Sigma–Aldrich, USA) supple-
mented with 19.2% heat-inactivated fetal calf serum, 1% streptomycin, 1% penicillin
and 2% (v/v) phytohemagglutinin (PHA, M Form, #10576015, Life Technologies,
USA). Lymphocytes were cultured for 72 h (37 C, humidiﬁed atmosphere with 5%
CO2). Forty-four hours after PHA stimulation, 3 lg/ml of cytochalasin B (Sigma–
Aldrich, USA) was applied to all cultures. Cytochalasin B is an inhibitor of actin poly-
merization, which prevents the separation of daughter cells after mitosis and, then,
leads to binucleated cells (Carter, 1967). Cultures were harvested 28 h after cyto-
chalasin B addition.
Cellular suspension was centrifuged at 1000 rpm for 5 min. Then, cells were
resuspended in a mild hypotonic treatment (KCl 0.075 M) maintained at 4 C for
3 min. Subsequently, the cells were centrifuged and a methanol/acetic acid (5:1)
solution was gently added. The ﬁxation step was repeated twice in methanol/acetic
acid (3:1) and ﬁnally, cells were deposited onto clean slides. The slides were stained
with 10% Giemsa (pH 6.8) for 3–4 min. Slides were mounted and coded prior to the
microscopic analysis.
The frequency and the distribution per cell of MN were determined by analyz-
ing 2000 binucleated cells with well-preserved cytoplasm obtained from each ani-
mal. The identiﬁcation of MN was carried out as previously described (Fenech,
1993). MN were identiﬁed as structures that appeared separated from the nucleus,
were round or oval, showed staining characteristics similar to those of the nuclei,
and were smaller in size than one-third of the area of the original nucleus. All anal-
yses were performed in a blind test.2.5.2. Alkaline comet assay
Considering our previous observation that the highest CA effect in lymphocyte
culture occurs after 3 days, peripheral blood samples were collected from C. apella
for alkaline comet assay (single-cell gel electrophoresis) analysis 72 h after CP, CA
or CP + CA treatments (Fig. 1). A blood sample was collected 48 h after CP treatment
from one animal of the CP group, due to the process of euthanasia (day 22).
Peripheral blood lymphocytes were isolated by Ficoll density gradient (Hyst-
opaque 1077, Sigma–Aldrich, USA). Before the comet assay, the cell viability was
analyzed by trypan blue exclusion. Lymphocytes were stained with 0.25% (w/v) try-
pan blue (T8154, Sigma–Aldrich, USA). The unstained (viable) cells were counted
under light microscopy. One hundred cells were counted to determine the percent-
age of viable cells excluding trypan blue. All samples presented cell viability greater
than 75% and were used for the comet assay.
Alkaline comet assay was performed as described by Singh et al. (1988), with
minor modiﬁcations. Lymphocytes were mixed with low-melting-point agarose.
Slides were prepared in duplicate and 100 nucleoids were screened per sample
(50 cells from each duplicate slide) with a ﬂuorescence microscope (Olympus,
USA). Undamaged cells appeared as intact nuclei without tails, whereas damaged
cells had the appearance of a comet. Comets were classiﬁed visually as belonging
to one of ﬁve classes according to tail size into ﬁve classes: 0, undamaged; 1, low
damage; 2, medium damage; 3, high damage; and 4, almost all DNA in the tail
(maximally damaged). The total number of comets for each class was multiplied
by the value of its class, thus creating an arbitrary unit (score). Therefore, the total
score for 100 comets can range from 0 (all undamaged) to 400 (all maximally dam-
aged) (Speit and Hartmann, 1999). The DNA damage index (DI) is based on the
length of migration and on the amount of DNA in the tail and is considered a sen-
sitive measure of DNA damage.
2.6. Statistical analysis
In the present study, only non-parametric tests were applied. Kruskal–Wallis
followed by the Games-Howell post hoc test were performed to compare the body
weight, serum biochemistry values, hematological parameters, MN frequencies and
DNA DI among CP, CA and CP + CA groups. Friedman was performed to compare MN
frequency, number of comets and DNA DI among treatments. The Wilcoxon’s test
with Bonferroni correction were applied as a post hoc analysis for the Friedman’s
test. The correlations between WBC or lymphocyte count (using as base value only
the analyses of day 0), MN frequency and DNA DI were analyzed by the Spearman’s
test, in which a Rho (q) value below 0.30 was determined as a weak correlation;
0.30–0.70 as a medium correlation; and above 0.70 as a strong correlation. In all
analyses, p values less than 0.05 were considered signiﬁcant.
3. Results
3.1. CP serious adverse side effects in C. apella
In baseline (days 1 and 0), none of hematological and biochem-
istry parameters, as well as the body weight, differed among
groups. During the study, two animals from the CP group were sac-
riﬁced on days 22 and 24 due to the presence of serious adverse
side effect (Fig. 1).
The two euthanized animals presented reduced WBC count of
2.64 and 1.75  103/lL, sleepiness, giddiness, loss of balance, low
food consumption, nonspeciﬁc gastrointestinal symptoms (diar-
rhea and vomiting), cutaneous eruptions and caustic and ulcerative
oral lesions. Before the sacriﬁce of these animals, they also pre-
sented renal and respiratory failure, hypokalemia, and elevation
of alanine aminotransferase, bilirubin, creatinine, and phosphorus
levels.
The necropsy showed renal damage with degeneration of adi-
pose tissue, hepatic venoocclusive disease, inﬂammatory lesions
of the gastrointestinal system, atrophy of villi and sterile hemor-
rhagic cystitis (noninfectious). No sign of pneumonia was observed
in the two euthanized animals. These ﬁndings suggested that these
two animals presented CP intoxication.
In addition, the two euthanized animals presented small her-
pesvirus lesions on the tongue, lips and/or skin. These two animals
presented more lesions than the other two CP-treated animals. In a
small number, the herpesvirus lesions were also detected in the
animals of CP + CA group. However, after the end of the present
study, no animal presented herpesvirus lesions.
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side effects. They were clinically monitored for one year after the
end of the experiment and they did not show complications result-
ing from the CP or CA treatments.3.2. CA effects in CP-treated C. apella
During the study, the body weight differed among groups on
days 7–29 and 32–36 (p < 0.05 for all comparisons, Kruskal–Wallis
test). The Games-Howell post hoc analyses showed that the body
weight was signiﬁcantly lower in the CP group than in the CA
group on all these days (p < 0.05). The CP group also presented low-
er weight than CP + CA group on days 18 and 20 (p < 0.05). More-
over, the CP + CA group presented lower weight than the CA
group on days 23–29 and 35 (p < 0.05) (Fig. 2, Supplementary Table
1).
The CA induced a slight increase of WBC count in the CA group.
The main effect of CA on WBC count of C. apellawas on the 5th day
(Fig. 3A, Supplementary Table 2). The WBC count differed among
groups on days 4–9, 22–30, and 40 (p < 0.05 for all comparisons,
Kruskal–Wallis test). The CP group presented a lower WBC count
than the CA group on days 4–9, 22–24, 26, 28–30 and 40, and lower
than the CP + CA group on days 4, 23–24, 26, 28–29 (p < 0.05 for all
comparisons, Games-Howell post hoc analysis). Moreover, the
CP + CA group presented a lowerWBC count than CA group on days
4–7 and 22–30 (p < 0.05 for all comparisons). Considering the nor-
mal limit of WBC count of 4.3–12.15  103/lL (Riviello and Wirz,
2001), no animals from the CA and CP + CA groups presented
abnormal WBC count. In the CP group, two animals presented a
WBC count below the normal limit on days 4 and 5. TheWBC count
of these two animals returned to the normal limit before the sec-
ond CP dose. However, animals from the CP group returned to
present abnormal WBC count after the second treatment and two
animals were sacriﬁced due to serious adverse side effects (days
22 and 24; Fig. 3A, Supplementary Table 2).
In the CP and CP + CA groups, the WBC count reduction was due
to a signiﬁcant reduction in the number of lymphocytes and of
neutrophils (Fig. 3B and C, Supplementary Table 2). CA was able
to induce an increase of lymphocyte count in CP-treated animals
since it was possible to observe that lymphocytes were signiﬁ-
cantly lower in the CP than in the CP + CA group on days 3–22,
24–29 and 32 (p < 0.05 for all comparison, Games-Howell post
hoc analysis for Kruskal–Wallis test). Moreover, all animals in theFig. 2. Median and range of body weight of Cebus apella by day. CP group: animals tha
received only Canova medicine. CP + CA group: animals that received Canova medicine w
CP and CA groups (p < 0.05) by Games-Howell post hoc analysis for Kruskal–Wallis test;
post hoc analysis for Kruskal–Wallis test; #, signiﬁcant difference between CA and CP + CA
line: highest and lowest value observed in the baseline.CP group and no animals from the CA and CP + CA groups pre-
sented abnormal count of lymphocytes.
Neutrophils were also signiﬁcantly lower in the CP than the
CP + CA group on days 9–15, 18–20, 25, 27–30, 33, 35–37, and 39
(p < 0.05 for all comparisons, Games-Howell post hoc analysis for
Kruskal–Wallis test). The eosinophil counts did not differ between
groups. No group presented monocytes and basophils in blood
samples.
The erythrocyte count differed among groups on days 2–14, 20–
21, 23–39 (p < 0.05 for all comparisons, Kruskal–Wallis test). The
erythrocyte count was also reduced to abnormal values with CP
treatment in CP and CP + CA groups. However, the number of
erythrocytes was signiﬁcantly lower in the CP than the CP + CA
group on days 2, 4–9, 34, and 38–39 (p < 0.05 for all comparisons,
Games-Howell post hoc analysis for Kruskal–Wallis test; Fig. 3D,
Supplementary Table 2).
The urea nitrogen level was higher in the CP and CP + CA groups
than in the CA group during most of the studied days (Fig. 4A, Sup-
plementary Table 3). The Games-Howell post hoc analysis for Krus-
kal–Wallis test showed that urea nitrogen level was signiﬁcantly
higher in the CP group than CP + CA group on days 3–6, 8–9, 25–
26 (p < 0.05 for all comparisons), demonstrating a CA effect on
CP-treated animals. Moreover, all animals of the CP group and no
animal from the CA presented increased values of urea nitrogen.
The creatinine level differed among groups on several days
(Fig. 4B). Creatinine level was signiﬁcantly higher in the CP group
than the CP + CA group on days 25–26 and 33–34 (p < 0.05 for all
comparisons, Games-Howell post hoc analysis for Kruskal–Wallis
test). According to the normal levels of C. apella serum chemistry
values, only two animals from the CP group presented abnormal
values of creatinine. The animals showing elevated values were
those that were sacriﬁced after the second CP treatment.
The phosphorus (Fig. 4C), alanine aminotransferase (Fig. 4D),
and total bilirubin (Fig. 4E) levels were signiﬁcantly higher in the
CP and CP + CA groups than in the CA group during several days
(Supplementary Table 3). However, no signiﬁcant effect of CA
was observed in CP-treated animals since any difference between
CP and CP + CA groups was detected. According to the normal lev-
els of total bilirubin in C. apella, only two animals from the CP
group presented abnormal values of total bilirubin, as well as cre-
atinine, and were those that were sacriﬁced after the second CP
treatment.
The albumin level was reduced due to CP treatment in CP and
CP + CA group compared to CA group on days 30–40 (p < 0.05 fort received 50 mg/kg cyclophosphamide on days 1 and 20. CA group: animals that
ith 50 mg/kg cyclophosphamide on days 1 and 20. , Signiﬁcant difference between
+, signiﬁcant difference between CP and CP + CA groups (p < 0.05) by Games-Howell
groups (p < 0.05) by Games-Howell post hoc analysis for Kruskal–Wallis test. Black
Fig. 3. Median and range of hematological parameters of Cebus apella by day. (a) WBC count; (b) lymphocytes; (c) neutrophils; (d) erythrocytes. CP group: animals that
received 50 mg/kg cyclophosphamide on days 1 and 20. CA group: animals that received only Canova medicine. CP + CA group: animals that received Canova medicine with
50 mg/kg cyclophosphamide on days 1 and 20. , Signiﬁcant difference between CP and CA groups (p < 0.05) by Games-Howell post hoc analysis for Kruskal–Wallis test; +,
signiﬁcant difference between CP and CP + CA groups (p < 0.05) by Games-Howell post hoc analysis for Kruskal–Wallis test; #, signiﬁcant difference between CA and CP + CA
groups (p < 0.05) by Games-Howell post hoc analysis for Kruskal–Wallis test. Black line: highest and lowest value observed in the baseline. Gray line: highest and lowest value
reported in normal adult C. apella by Riviello and Wirz (2001).
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Fig. 4. Median and range of biochemical parameters of Cebus apella by day. (a) Urea nitrogen; (b) creatinine; (c) phosphorus; (d) alanine aminotransferase; (e) total bilirubin;
(f) albumin; (g) triglycerides; (h) glucose levels. CP group: animals that received 50 mg/kg cyclophosphamide on days 1 and 20. CA group: animals that received only Canova
medicine. CP + CA group: animals that received Canova medicine with 50 mg/kg cyclophosphamide on days 1 and 20. , Signiﬁcant difference between CP and CA groups
(p < 0.05) by Games-Howell post hoc analysis for Kruskal–Wallis test; +, signiﬁcant difference between CP and CP + CA groups (p < 0.05) by Games-Howell post hoc analysis
for Kruskal–Wallis test; #, signiﬁcant difference between CA and CP + CA groups (p < 0.05) by Games-Howell post hoc analysis for Kruskal–Wallis test. Black line: highest and
lowest value observed in the baseline. Gray line: highest and lowest value reported in normal adult C. apella by Riviello and Wirz (2001).
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lis test; Fig. 4F, Supplementary Table 3). Furthermore, only one ani-
mal from the CP group presented abnormal triglyceride level
(Fig. 4G) and no animal show abnormal glucose level (Fig. 4H, Sup-
plementary Table 3). The CP group exhibited a signiﬁcantly higher
triglyceride level than the CP + CA group on day 20, and between
days 32 and 40 (p < 0.05 for all comparisons, Games-Howell post
hoc analysis for Kruskal–Wallis test). Moreover, the CP group pre-
sented lower glucose than the CP + CA group on days 3 and 4
(p = <0.05).
3.3. CA effects on MN frequency and lymphocyte DNA damage in
CP-treated C. apella
Table 1 shows the MN distribution in binucleated cells from
C. apella, before and after the ﬁrst or the second round of treat-
ments in the CP, the CA and the CP + CA groups. We observed that
the distribution of the MN number, the mean MN per 1000 binu-
cleated cells, and the total number of binucleated cells presenting
MN, differed among the three days of analyses only in the CP and
the CA + CP groups (p < 0.05 for all comparisons, Friedman test).
However, we were not able to demonstrate any signiﬁcant differ-
ence among treatments after post hoc analyses.Before treatments, the MN frequency differed among the three
groups (p < 0.05, Kruskal–Wallis test). The Games-Howell post hoc
analyses demonstrated a higher MN frequency in the CP + CA
group compared to the CA group (p < 0.05) in the baseline. How-
ever, lymphocytes presented more frequently one MN by binucle-
ated cell and the number of MN by animal was very small (2–6
MN/1000 binucleated cells) in all groups.
The MN frequency differed among groups after the ﬁrst
(p < 0.01, Kruskal–Wallis test) and the second (p < 0.01) round of
treatments. After the ﬁrst CP and/or CA treatment, the post hoc
analyses showed that the MN frequency was higher in the CP
group compared to the CA (p < 0.001) and to the CP + CA
(p < 0.001) groups, and that the CP + CA group presented a higher
frequency of MN compared to the CA group (p = 0.001). After the
second dose of treatment, the CP group also presented a higher
MN frequency than the CA (p < 0.001) and the CP + CA (p < 0.01)
groups, and the CP + CA group presented a higher frequency of
MN compared to the CA group (p < 0.01).
The number of cells presenting 1, 2, or 3 MN and the total num-
ber of binucleated cells presenting MN differed among groups after
the ﬁrst and second round of treatments (p < 0.05 for all compari-
sons, Kruskal–Wallis test). The Games-Howell analyses showed
that the CP group presented more MN than the CP + CA group,
Table 1
Micronuclei distribution in binucleated cells from Cebus apella treated with cyclophosphamide and/or Canova.
Treatment Distribution of MN in BN [median (IR)] Total of MN MN/1000 BN [median (IR)]
1 MN 2 MN 3 MN
CP group
Before treatmenta 2.00 (0.25) 0.50 (0.75) 0.00 (0.00) 3.50 (3.75) 1.75 (0.88)
First treatment 172.50 (9.75) 60.00 (6.00) 25.00 (6.75) 367.00 (13.50) 183.75 (6.75)
Second treatment 181.50 (15.00)b 67.50 (6.00)b 30.50 (7.00)b 408.00 (7.50)b 204.00 (3.75)b
CA group
Before treatmenta 2.00 (0.50) 0.50 (1.00) 0.00 (0.00) 2.00 (0.50) 1.00 (0.25)
First treatment 3.00 (0.5)d 0.50 (1.0)d 0.00 (0.00)d 4.00 (2.50)d 2.00 (1.25)d
Second treatment 2.50 (1.5)f 0.00 (0.5)f 0.00 (0.25)f 3.50 (2.25)f 1.75 (1.13)f
CP + CA group
Before treatmenta 3.00 (0.25) 1.00 (0.24) 0.00 (0.00) 5.00 (0.25) 2.50 (0.13)c
First treatment 67.00 (5.75)d,e 42.50 (5.00)d,e 9.50 (4.75)d 179.00 (29.50)d,e 89.75 (14.75)d,e
Second treatment 77.50 (11.75)b,f,g 47.50 (7.50)b,f,g 11.00 (7.50)b,f 204.50 (50.25)b,f,g 102.25 (25.13)b,f,g
MN, micronuclei according Fenech (1993); BN, binucleated cells. IR: interquartile range. 8000 cells were analyzed per treatment for MN score, in which 1 MN represents the
binucleated cells presenting one MN, and so on. CP group: animals that received 50 mg/kg cyclophosphamide on days 1 and 20. CA group: animals that received only Canova
medicine. CP + CA group: animals that received Canova medicine with 50 mg/kg cyclophosphamide on days 1 and 20. Peripheral blood samples for lymphocyte-MN assay
were collected 24 h after CP, CA, or CP + CA treatments.
a Day 0
b Signiﬁcant difference among treatments (p < 0.05), intragroup analysis by Friedman test.
c Signiﬁcant difference compared to the CA group in the baseline (p < 0.05), by Games-Howell post hoc analysis for Kruskal–Wallis test.
d Signiﬁcant difference compared to the CP group after the ﬁrst treatment (p < 0.05), by Games-Howell post hoc analysis for Kruskal–Wallis test.
e Signiﬁcant difference compared to the CA group after the ﬁrst treatment (p < 0.05), by Games-Howell post hoc analysis. for Kruskal–Wallis test
f Signiﬁcant difference compared to the CP group after the second treatment (p < 0.05), by Games-Howell post hoc analysis for Kruskal–Wallis test.
g Signiﬁcant difference compared to the CA group after the second treatment (p < 0.05), by Games-Howell post hoc analysis for Kruskal–Wallis test.
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second treatments (p < 0.05 for all comparisons). For the compari-
son of the number of cells presenting 3 MN between the CA and
CP + CA group after the second round of treatment, we did not ob-
serve a signiﬁcant difference.
In addition, the frequency of MN was inversely correlated to
WBC and to lymphocyte count in the CP (p < 0.01, q = 0.746;
p < 0.01, q = 0.818, respectively; Spearman correlation) and
CP + CA (p < 0.05, q = 0.669; p < 0.001, q = 0.944, respectively)
groups.
Table 2 shows the DNA damage scores and index by the comet
assay in C. apella from the CP, CA, and CP + CA groups. We also ob-
served that comet classes 1, 3 and 4 and DNA DI differed among
baseline, as well as the ﬁrst and the second doses of CP in CP andTable 2
DNA damage scores and index by comet assay in Cebus apella treated with cyclophospham
Treatment DNA damage score [median (IR)]
0 1 2
CP group
Before treatmenta 78.25 (6.25) 12.50 (1.63) 9.00 (3.00)
First treatment 67.00 (2.75) 15.75 (1.13) 14.50 (1.38
Second treatment 56.50 (3.00)b 21.00 (2.38)b 14.75 (0.75
CA group
Before treatmenta 79.25 (1.00) 12.25 (2.88) 8.25 (2.88)
First treatment 81.25 (3.88) 11.50 (2.50) 5.75 (2.38)
Second treatment 80.75 (2.00) 12.00 (6.00) 7.75 (2.13)
CP + CA group
Before treatmenta 78.00 (1.00) 11.50 (0.38) 9.25 (1.00)
First treatment 71.50 (0.63) 17.00 (1.50) 11.00 (0.63
Second treatment 65.75 (0.88)b 18.75 (1.00)b 12.50 (1.90
IR, interquartile range; DI, damage index. 400 cells were analyzed per treatment for DNA d
on days 1 and 20. CA group: animals that received only Canova medicine. CP + CA group:
and 20. Peripheral blood samples for comet assay were collected 72 h after CP, CA, or C
a Day 0.
b Signiﬁcant difference among treatments (p < 0.05), intragroup analysis by Friedman
c Signiﬁcant difference compared to the CP group after the ﬁrst treatment (p < 0.05),
d Signiﬁcant difference compared to the CA group after the ﬁrst treatment (p < 0.05),
e Signiﬁcant difference compared to the CP group after the second treatment (p < 0.05
f Signiﬁcant difference compared to the CA group after the second treatment (p < 0.0CA + CP groups (p < 0.05 for all comparisons, Friedman test). In
addition, comet class 2 also differed among the analyzed days in
the CP group (p < 0.05). However, we were not able to demonstrate
any signiﬁcant difference among treatments after post hoc
analyses.
The DNA DI did not differ signiﬁcantly among groups in the
baseline and differed signiﬁcantly among groups after the ﬁrst
(p < 0.01, Kruskal–Wallis test) and second treatments (p < 0.01).
The Games-Howell post hoc analyses showed that DNA DI was sig-
niﬁcantly higher in the CP group than the CA group after the ﬁrst
(p = 0.001) and second (p = 0.001) treatments. Moreover, the CP
group presented higher DNA DI than the CP + CA group after the
second round of treatment, but this was not statistically signiﬁ-
cant. Only a tendency to present a higher DNA DI was observedide and/or Canova.
DNA DI [Median (IR)]
3 4
0.50 (0.38) 0.00 (0.00) 33.50 (8.75)
) 1.75 (0.88) 0.50 (1.13) 53.00 (6.00)
)b 4.00 (1.13)b 2.50 (1.13)b 74.25 (5.75)b
0.5 (0.5) 0.00 (0.00) 29.50 (4.63)
c 0.75 (0.63) 0.00 (0.13) 26.25 (5.63)c
e 0.50 (0.38)e 0.00 (0.00)e 28.25 (4.63)e
0.75 (0.63) 0.00 (0.00) 33.75 (2.00)
)d 1.00 (0.25) 0.00 (0.00) 41.00 (1.50)d
) 1.75 (0.63)b,e 0.75 (0.63)b,e,f 52.75 (2.13)b,e,f
amage index analysis. CP group: animals that received 50 mg/kg cyclophosphamide
animals that received Canova medicine with 50 mg/kg cyclophosphamide on days 1
P + CA treatments.
test.
by Games-Howell post hoc analysis for Kruskal–Wallis test.
by Games-Howell post hoc analysis for Kruskal–Wallis test.
), by Games-Howell post hoc analysis for Kruskal–Wallis test.
5), by Games-Howell post hoc analysis for Kruskal–Wallis test.
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of treatment (not statistically signiﬁcant). In addition, the CP + CA
group presented a signiﬁcantly higher DNA DI than the CA group
after the ﬁrst (p < 0.01) and the second (p < 0.001) CP treatment.
A higher frequency of comet class 2 was also observed in the CP
(p < 0.05, Games-Howell post hoc analysis) and CP + CA (p < 0.05)
groups compared to the CA group after the ﬁrst treatment. After
the second CP treatment, the distribution of comets classes 2, 3
and 4 also increased in the CP group compared to CA group
(p < 0.05, p = 0.001, p < 0.05, respectively). The CP group also pre-
sented a higher frequency of comets class 3 and 4 compared to
the CP + CA group after the second treatment (p = 0.009, p < 0.05,
respectively). After the second CP treatment, the CP + CA group
also presented a higher frequency of comet class 4 compared to
the CA group (p < 0.05).
In addition, a direct correlation was observed between the fre-
quency of MN and DNA DI in the CP (p < 0.001, q = 0.951; Spear-
man correlation) and CP + CA (p < 0.01, q = 0.761) groups.
Furthermore, the DNA DI was inversely correlated to WBC and
lymphocyte count in the CP (p < 0.01, q = 0.8; p = 0.001,
q = 0.864, respectively) and CP + CA (p < 0.05, q = 0.783;
p < 0.01, q = 0.797, respectively) groups.4. Discussion
In the present study, the CP + CA group presented body weight
and hematology data between CP and CA groups. On the other
hand, the serum chemistry values observed in the CP + CA group
showed an outcome more close to the CP group and different from
the CA group. Thus, at the dose levels given, CA seems to present a
reduced effect regarding liver and kidney toxicity when compared
to myelotocicity and body weight effect. Since the CP + CA group
received CA and CP drugs at the same time and via the same route,
we cannot exclude that CA components may interact with CP be-
fore the CP exerts its toxic action, reducing the exposure of the ani-
mal to CP.
In this study, animals of CP + CA group presented higher num-
ber of WBC, lymphocytes, erythrocytes and neutrophils compared
to animals treated only with CP. This ﬁnding allows some hypoth-
esis. Firstly, CA may up-regulate these cells in non-human prima-
tes treated with CP. It was previously reported that CA can
increase directly or indirectly the number of lymphocytes (Coelho
Moreira et al., 2012; Sato et al., 2005). In addition, Abud et al.
(2006) suggested that CA medicine also facilitates the production
of erythroid differentiation regulator, which would justify the in-
crease of erythrocytes in the peripheral blood of C. apella treated
with CP + CA compared to the CP group in some periods of this
study. However, further analyses are necessary to understand
how CA may act in neutrophils count.
Secondly, CA may have a cytoprotective effect on cells vulnera-
ble to CP effects. This cyprotective effect might also lead to the
reduction of DNA damage in the CP + CA group compared to the
CP group. CP induces toxicity through its enzymatic conversion
to active alkylating intermediates by cytochrome P-450 (CYP)
monooxygenases. The CYP2B and 2C subfamily enzymes are
mainly responsible for the convertion of CP into its active metabo-
lites acrolein and phosphoramide mustard (Yu et al., 1999), while
CYP3A enzymes metabolize CP to dechloroethylcyclophosphamide
and chloroacetaldehyde and seem to play a key role in the detox-
iﬁcation of this akylating agent (Yu et al., 1999).
CA is a complex homeopathic medicine and the effect of its
compound is not completely understood. It was previously re-
ported that Asa foetida, a CA compound, is able to reduce the levels
of cytochrome P450 and b5 and restore the antioxidant system in
MNU-induced mammary carcinogenesis in rats (Mallikarjuna et al.,2003). On the other hand, Lycopodium clavatum, another CA com-
pound, may have potential to inactivate CYP3A4 (Tam et al.,
2011). Since some plant extracts are able to modify the expression
and activity of CYP enzymes and, thus, may alter the activation or
detoxiﬁcation of CP (Bagchi et al., 2002; Kumarappan et al., 2011;
Ray et al., 2001), further studies are necessary to evaluate whether
CA has a cytoprotector effect in vivo and in its target cells and, then,
determine if CA may be used as a chemopreventive agent in the
treatment of solid tumors.
Thirdly, CA may inhibit CP-mediated leukocytopenia and lym-
phocytopenia. Thus, our ﬁndings suggest that CA treatment mini-
mizes CP myelotoxicity in C. apella. The CA effects on WBC count,
especially lymphocytes, may have human therapeutic applications
such as restoring the hematopoietic system after chemotherapy for
solid tumors.
Concerning serum chemistry values, the highest difference be-
tween groups was observed in urea nitrogen and creatinine levels,
indicators of glomerular function of the kidney. CP is nephrotoxic
besides being urotoxic thereby limiting its clinical utility (Hamsa
and Kuttan, 2011). Here, we observed that CP induced an increase
in urea nitrogen and creatinine level, as well as other parameters
related to renal damage, compared to the pretreatment serum level
of C. apella. However, the CP group presented a signiﬁcant increase
of this parameter compared to the CP + CA group. Thus, this study
shows that CA treatment may have a role in the reduction of CP-
induced renal damage. However, additional investigations are nec-
essary to evaluate if CA may act in renal cells.
5. Conclusions
CP induced abnormal WBC count, MN and DNA damage in all
animals. However, CA treated animals presented a higher leuko-
cyte count than the animals without this treatment. Moreover,
CA-treated animals presented lower frequency of MN and DNA
damage than animals without this medicine. Thus, CA treatment
minimizes CP myelotoxicity in C. apella.
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